Ficoxil Tuggutafla 227 mg Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

ficoxil tuggutafla 227 mg

livisto int'l, s.l. - firocoxibum inn - tuggutafla - 227 mg

Ficoxil Tuggutafla 57 mg Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

ficoxil tuggutafla 57 mg

livisto int'l, s.l. - firocoxibum inn - tuggutafla - 57 mg

Losartan/Hydrochlorothiazide Medical Valley (Licolos plus) Filmuhúðuð tafla 100/25 mg Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

losartan/hydrochlorothiazide medical valley (licolos plus) filmuhúðuð tafla 100/25 mg

medical valley invest ab - hydrochlorothiazidum inn; losartanum kalíum - filmuhúðuð tafla - 100/25 mg

Losartan/Hydrochlorothiazide Medical Valley (Licolos plus) Filmuhúðuð tafla 50/12,5 mg Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

losartan/hydrochlorothiazide medical valley (licolos plus) filmuhúðuð tafla 50/12,5 mg

medical valley invest ab - losartanum kalíum; hydrochlorothiazidum inn - filmuhúðuð tafla - 50/12,5 mg

Dermatin Hársápa 20 mg/g Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

dermatin hársápa 20 mg/g

teva b.v.* - ketoconazolum inn - hársápa - 20 mg/g

Terbinafin Actavis Tafla 250 mg Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

terbinafin actavis tafla 250 mg

actavis group ptc ehf. - terbinafinum hýdróklóríð - tafla - 250 mg

Terbinafin Medical Valley Tafla 250 mg Iceland - Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

terbinafin medical valley tafla 250 mg

medical valley invest ab - terbinafinum hýdróklóríð - tafla - 250 mg

Clopidogrel Acino Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

clopidogrel acino

acino ag - klópídógrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - blóðþurrðandi lyf - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Clopidogrel Acino Pharma Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

clopidogrel acino pharma

acino pharma gmbh - klópídógrel - peripheral vascular diseases; stroke; myocardial infarction - blóðþurrðandi lyf - eða er ætlað í fullorðnir til að fyrirbyggja atherothrombotic atburðum í:sjúklingar sem þjáist af kransæðastíflu (frá nokkrum dögum fyrr en minna en 35 dögum), blóðþurrðar heilablóðfall (frá 7 daga þar til að minna en 6 mánuðum) eða komið útlæga slagæð sjúkdómur. nánari upplýsingar er að vísa til kafla 5.

Clopidogrel Acino Pharma GmbH Kesatuan Eropah - Iceland - EMA (European Medicines Agency)

clopidogrel acino pharma gmbh

acino pharma gmbh - klópídógrel - peripheral vascular diseases; stroke; myocardial infarction - blóðþurrðandi lyf - eða er ætlað í fullorðnir til að fyrirbyggja atherothrombotic atburðum í:sjúklingar sem þjáist af kransæðastíflu (frá nokkrum dögum fyrr en minna en 35 dögum), blóðþurrðar heilablóðfall (frá 7 daga þar til að minna en 6 mánuðum) eða komið útlæga slagæð sjúkdómur. nánari upplýsingar er að vísa til kafla 5.